

References for GI Risk Stratification

- Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. *Am J Gastroenterol*. 2016;111(1):30-50; quiz 51.
- American Gastroenterological A, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology*. 2011;140(3):1084-1091.
- Asge Standards of Practice C, Qumseya B, Sultan S, et al. ASGE guideline on screening and surveillance of Barrett's esophagus. *Gastrointest Endosc*. 2019;90(3):335-359 e332.
- Fitzgerald RC, di Pietro M, Ragnath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. *Gut*. 2014;63(1):7-42.
- Konda VJA, Souza RF. Barrett's Esophagus and Esophageal Carcinoma: Can Biomarkers Guide Clinical Practice? *Curr Gastroenterol Rep*. 2019;21(4):14.
- Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus. *Gastrointest Endosc*. 2019;90(5):707-717 e701.
- Dam AN, Klapman J. A narrative review of Barrett's esophagus in 2020, molecular and clinical update. *Ann Transl Med*. 2020;8(17):1107.
- Souza RF, Spechler SJ. Advances in Biomarkers for Risk Stratification in Barrett's Esophagus. *Gastrointest Endosc Clin N Am*. 2021;31(1):105-115.
- Iyer PG, Katzka DA. Nonendoscopic Detection of Barrett Esophagus and Esophageal Adenocarcinoma: Recent Advances and Implications. *Ann Intern Med*. 2021;174(7):1006-1007.
- Kolb JM, Wani S. A Paradigm Shift in Screening for Barrett's Esophagus: The BEST Is Yet to Come. *Gastroenterology*. 2021;160(1):467-469.
- Yusuf A, Fitzgerald RC. Screening for Barrett's Oesophagus: Are We Ready for it? *Curr Treat Options Gastroenterol*. 2021:1-16.
- Offman J, Fitzgerald RC. Alternatives to Traditional Per-Oral Endoscopy for Screening. *Gastrointest Endosc Clin N Am*. 2017;27(3):379-396.
- Ross-Innes CS, Chettouh H, Achilleos A, et al. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. *Lancet Gastroenterol Hepatol*. 2017;2(1):23-31.
- Moinova HR, LaFramboise T, Lutterbaugh JD, et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. *Sci Transl Med*. 2018;10(424).

Iyer PG, Taylor WR, Johnson ML, et al. Highly Discriminant Methylated DNA Markers for the Non-endoscopic Detection of Barrett's Esophagus. *Am J Gastroenterol*. 2018;113(8):1156-1166.

Chettouh H, Mowforth O, Galeano-Dalmau N, et al. Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. *Gut*. 2018;67(11):1942-1949.

Wang Z, Kambhampati S, Cheng Y, et al. Methylation Biomarker Panel Performance in EsophCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study. *Clin Cancer Res*. 2019;25(7):2127-2135.

Fitzgerald RC, di Pietro M, O'Donovan M, et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. *Lancet*. 2020;396(10247):333-344.

Iyer PG, Taylor WR, Johnson ML, et al. Accurate Nonendoscopic Detection of Barrett's Esophagus by Methylated DNA Markers: A Multisite Case Control Study. *Am J Gastroenterol*. 2020;115(8):1201-1209.

Iyer PG, Taylor WR, Slettedahl SW, et al. Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett's esophagus in a multisite case-control study. *Gastrointest Endosc*. 2021.

Heberle CR, Omidvari AH, Ali A, et al. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. *Clin Gastroenterol Hepatol*. 2017;15(9):1397-1404 e1397.

Swart N, Maroni R, Muldrew B, et al. Economic evaluation of Cytosponge(R)-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data. *EClinicalMedicine*. 2021;37:100969.

Sami SS, Moriarty JP, Rosedahl JK, et al. Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening. *Am J Gastroenterol*. 2021.